Ranibizumab Does Not Worsen Retinal Degeneration in Intermediate AMD, Study Finds
A post hoc analysis of the PREVENT trial suggests quarterly ranibizumab did not appear to affect drusen volume, drusen area, or GA progression compared to sham.
Stay updated with breaking news from Scale Level. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A post hoc analysis of the PREVENT trial suggests quarterly ranibizumab did not appear to affect drusen volume, drusen area, or GA progression compared to sham.
Indian Army Recruitment 2022 Notification: Are you interested in joining the Indian Army? The Indian Army has announced a new job opportunity for both male and female applicants. Candidates interested in joining the Indian Army can apply at the official website.
Phase 3 study will focus on critically ill patients, many of whom have run out of effective drug treatment optionsTORONTO, ON / ACCESSWIRE / January 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage